Ligand News and Research

RSS

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.

7 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

New infrared spectroscopy technique to analyze pharmacological agent-protein interactions

RUB-Researchers from the Chair for Biophysics have developed a new method for the detailed study of the interaction between pharmaceuticals and their target proteins.

5 Sep 2012

CLC bio announces acquisition of Molegro

Today, CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.

3 Sep 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

TREM-1 gene disrupts inflammatory process implicated in liver cancer

Researchers at the Georgia Health Sciences University Cancer Center have identified a gene that disrupts the inflammatory process implicated in liver cancer.

23 Aug 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Five recent Science and Nature papers shed light on elusive 'GPCRs'

Readers of the top-ranked scientific journals Science and Nature might have noticed a recent wave of articles, most recently in the July 13, 2012 issue of Science, with deep importance for biology and medicine.

14 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

Sirnaomics, Inc. announced today that the company has been awarded another NIH SBIR grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.

25 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

Biomarkers predict progressive spinal damage in ankylosing spondylitis

German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.

8 Jun 2012